BioCentury
ARTICLE | Company News

Sorrento, 3SBio deal

June 13, 2016 7:00 AM UTC

Sorrento’s TNK Therapeutics Inc. subsidiary and 3SBio formed a JV focused on chimeric antigen receptor (CAR) T cell therapies. TNK will grant the JV rights in China, including Hong Kong and Macau, to CAR T technology targeting carcinoembryonic antigen (CEA)-positive cancers and two additional CARs for cellular therapy. ...